[{"id":"8061a0a4-90b7-438d-bd01-079e025dc238","acronym":"","url":"https://clinicaltrials.gov/study/NCT03113487","created_at":"2021-01-18T15:20:26.946Z","updated_at":"2025-02-25T14:01:16.153Z","phase":"Phase 2","brief_title":"P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT03113487","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • TP53 • MUC16","pipe":" | ","alterations":" TP53 mutation","tags":["PD-L1 • TP53 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • p53MVA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 08/26/2022","primary_completion_date":" 08/26/2022","study_txt":" Completion: 06/03/2025","study_completion_date":" 06/03/2025","last_update_posted":"2025-02-19"},{"id":"506639ea-1f9f-4169-b1e7-f028c834b64f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04870944","created_at":"2021-05-04T12:53:25.071Z","updated_at":"2025-02-25T15:12:04.041Z","phase":"Phase 1/2","brief_title":"CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma","source_id_and_acronym":"NCT04870944","lead_sponsor":"Children's Oncology Group","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CBL0137"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 01/28/2022","start_date":" 01/28/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-13"},{"id":"20ab3da1-4b1b-4645-a925-205f881a9a07","acronym":"","url":"https://clinicaltrials.gov/study/NCT02432963","created_at":"2021-01-17T18:04:39.866Z","updated_at":"2024-07-02T16:35:14.012Z","phase":"Phase 1","brief_title":"Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy","source_id_and_acronym":"NCT02432963","lead_sponsor":"City of Hope Medical Center","biomarkers":" TP53 • MSI","pipe":" | ","alterations":" TP53 mutation • TP53 expression • TP53 overexpression","tags":["TP53 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 expression • TP53 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • p53MVA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 06/14/2016","start_date":" 06/14/2016","primary_txt":" Primary completion: 12/04/2017","primary_completion_date":" 12/04/2017","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-19"},{"id":"75c79647-b107-47ed-9d39-fa812e55d7c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00082641","created_at":"2021-01-25T18:52:15.415Z","updated_at":"2024-07-02T16:35:35.972Z","phase":"Phase 1/2","brief_title":"Neoadjuvant/Adjuvant Chemotherapy, Vaccine \u0026 Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer","source_id_and_acronym":"NCT00082641","lead_sponsor":"University of Nebraska","biomarkers":" TP53","pipe":" | ","alterations":" TP53 overexpression","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • INGN 225"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 01/01/2004","start_date":" 01/01/2004","primary_txt":" Primary completion: 05/01/2009","primary_completion_date":" 05/01/2009","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2023-09-22"},{"id":"9d9db26b-7dbf-4a76-bf46-0a00a7f32042","acronym":"","url":"https://clinicaltrials.gov/study/NCT05093387","created_at":"2021-10-26T21:53:11.634Z","updated_at":"2024-07-02T16:36:00.404Z","phase":"Phase 1","brief_title":"SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer","source_id_and_acronym":"NCT05093387","lead_sponsor":"Northwestern University","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • SGT-53"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/10/2022","start_date":" 11/10/2022","primary_txt":" Primary completion: 11/10/2022","primary_completion_date":" 11/10/2022","study_txt":" Completion: 11/10/2022","study_completion_date":" 11/10/2022","last_update_posted":"2022-11-15"},{"id":"7cfa6f26-875f-4193-9aef-c545fb2ab82d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03554707","created_at":"2021-01-18T17:29:50.207Z","updated_at":"2024-07-02T16:36:17.444Z","phase":"Phase 1","brief_title":"SGT-53 in Children With Recurrent or Progressive CNS Malignancies","source_id_and_acronym":"NCT03554707","lead_sponsor":"SynerGene Therapeutics, Inc.","biomarkers":" MGMT • MDM2 • CDKN1A","pipe":" | ","alterations":" ATRX mutation • MDM2 mutation","tags":["MGMT • MDM2 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATRX mutation • MDM2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • temozolomide • irinotecan • Onivyde (nanoliposomal irinotecan) • SGT-53"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-02-08"},{"id":"868a48c8-2833-439b-b24b-719061743a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05113290","created_at":"2021-11-09T12:53:05.983Z","updated_at":"2024-07-02T16:36:17.880Z","phase":"Phase 4","brief_title":"Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment","source_id_and_acronym":"NCT05113290","lead_sponsor":"First Affiliated Hospital Xi'an Jiaotong University","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • Oncorine (recombinant human adenovirus type 5)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 12/28/2021","start_date":" 12/28/2021","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-01-27"},{"id":"e1aa1af2-37cc-42c0-a2d8-53d46106cce9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03544723","created_at":"2021-01-18T17:27:13.078Z","updated_at":"2024-07-02T16:36:44.349Z","phase":"Phase 2","brief_title":"Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.","source_id_and_acronym":"NCT03544723","lead_sponsor":"MultiVir, Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Ad-p53 gene therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 10/01/2018","start_date":" 10/01/2018","primary_txt":" Primary completion: 06/30/2022","primary_completion_date":" 06/30/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2020-06-09"},{"id":"d0b024e8-77de-4ee7-8bba-6a54661e6118","acronym":"COTI2-101","url":"https://clinicaltrials.gov/study/NCT02433626","created_at":"2021-01-18T11:39:07.906Z","updated_at":"2024-07-02T16:37:03.257Z","phase":"Phase 1","brief_title":"Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies","source_id_and_acronym":"NCT02433626 - COTI2-101","lead_sponsor":"Critical Outcome Technologies Inc.","biomarkers":" TP53 • MUC16","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • COTI-2"],"overall_status":"Unknown status","enrollment":" Enrollment 51","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 06/01/2020","study_completion_date":" 06/01/2020","last_update_posted":"2019-02-01"},{"id":"b4eb2ce4-ce5e-4719-a980-3012b29e1492","acronym":"","url":"https://clinicaltrials.gov/study/NCT02275039","created_at":"2021-01-18T10:42:22.245Z","updated_at":"2024-07-02T16:37:11.146Z","phase":"Phase 1","brief_title":"p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer","source_id_and_acronym":"NCT02275039","lead_sponsor":"City of Hope Medical Center","biomarkers":" TP53 • MUC16","pipe":" | ","alterations":" TP53 mutation • TP53 expression • TP53 overexpression","tags":["TP53 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 expression • TP53 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • p53MVA"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 04/23/2018","primary_completion_date":" 04/23/2018","study_txt":" Completion: 04/23/2018","study_completion_date":" 04/23/2018","last_update_posted":"2018-04-30"},{"id":"2886963b-a9f6-4428-8e57-0ed8bae6fca1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01191684","created_at":"2021-01-18T04:46:05.028Z","updated_at":"2024-07-02T16:37:19.347Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer","source_id_and_acronym":"NCT01191684","lead_sponsor":"City of Hope Medical Center","biomarkers":" EGFR • TP53","pipe":" | ","alterations":" TP53 expression • TP53 overexpression","tags":["EGFR • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression • TP53 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e p53MVA"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 08/01/2013","primary_completion_date":" 08/01/2013","study_txt":" Completion: 08/01/2013","study_completion_date":" 08/01/2013","last_update_posted":"2017-08-01"},{"id":"6dd650b0-d07e-40b8-81a5-bed6597d302d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02579564","created_at":"2021-01-18T12:30:32.393Z","updated_at":"2024-07-02T16:37:28.336Z","phase":"Phase 3","brief_title":"Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients","source_id_and_acronym":"NCT02579564","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" EGFR • MUC16","pipe":"","alterations":" ","tags":["EGFR • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • paclitaxel • pemetrexed • vinorelbine tartrate • Endostar (recombinant human endostatin) • Oncorine (recombinant human adenovirus type 5)"],"overall_status":"Unknown status","enrollment":" Enrollment 134","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2016-10-21"}]